Although lampalizumab that targets the alternative pathway failed to show clinical benefit in macular degeneration, alternative inhibitors are still in different phases of clinical development and include: Compstatin (C3 inhibitor) along with its derivatives APL-1 and APL-2 (Apellis Pharmaceuticals), Mirococept (APT070, C3 inhibitor), PMX-53 (C5a receptor antagonist), C1-INH (inhibits classical and lectin pathways), Tesidolumab (inhibitor of C5 activation) among others (163). The gene discussed is C3; the disease is macular degeneration.